HanchorBio Inc., a global biotechnology firm focused on developing advanced immunotherapies, has announced the publication of its research on HCB101 in the prestigious Journal of Hematology & Oncology. This peer-reviewed article highlights the innovative design and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein that targets the CD47-SIRPα pathway.
The publication, titled “HCB101: A Novel Potent Ligand-Trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors,” details the extensive protein engineering that facilitates the restoration of macrophage-mediated phagocytosis. This mechanism allows HCB101 to effectively connect innate and adaptive immune responses while minimizing binding to red blood cells.
In preclinical evaluations, HCB101 demonstrated significant efficacy across over 80 xenograft and patient-derived xenograft (PDX) models, with a safety profile that sets it apart from earlier CD47-targeting therapies. The high regard for this journal is evidenced by previous publications on similar therapies, underscoring its importance in the field.
“The publication in the Journal of Hematology & Oncology validates the scientific rigor and innovative approach that underpin HCB101,” stated Scott Liu, PhD, Chairman, CEO, and Founder of HanchorBio. “The clinical studies indicate that when combined with standard care, HCB101 has achieved a remarkable nearly 90% partial response rate in second-line gastric cancer at doses of 5.12 and 8.0 mg/kg. Additionally, we have successfully escalated the monotherapy dosage to 30 mg/kg without safety issues.”
This progress highlights HCB101″s potential as a foundational immunotherapy for solid tumors and hematologic cancers, paving the way for future applications in autoimmune conditions where the CD47-SIRPα pathway may also play a crucial role.
HCB101 is currently undergoing multinational Phase 1 and Phase 1b/2a clinical trials. Dr. Wenwu Zhai, the Chief Scientific Officer of HanchorBio, emphasized that the findings published in JHO confirm the effectiveness of the design strategy that led to HCB101, which balances strong efficacy with a clean safety profile—an area where previous CD47-targeting agents have struggled.
“The translation of our preclinical findings into effective monotherapy and combination therapies in gastric cancer strengthens our confidence in exploring HCB101″s applications beyond oncology, particularly in autoimmunity,” Zhai added.
About HCB101: HCB101 is classified as a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein that maintains intact IgG4 effector functionality. It was developed using HanchorBio”s proprietary FBDBTM platform, designed to selectively target CD47 on tumors while exhibiting minimal affinity for red blood cells. This characteristic helps avoid the hematologic toxicities that are often associated with anti-CD47 monoclonal antibodies, while still promoting strong antibody-dependent cellular phagocytosis (ADCP) and facilitating the immune system”s adaptive responses.
About HanchorBio: Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is an innovative biotechnology company specializing in immuno-oncology. The organization is led by a team of seasoned professionals from the pharmaceutical industry, dedicated to revolutionizing cancer treatments. HanchorBio is committed to revitalizing the immune response to combat diseases, leveraging its proprietary FBDBTM platform to develop unique biologics that engage both innate and adaptive immunity, aiming to overcome the challenges faced by current anti-PD1/L1 therapies. For additional information, please visit: www.HanchorBio.com.
